tiprankstipranks
Analyst Profile
Followed by 158 other investors
.
Derek Archila

Derek Archila

Wells Fargo
Wall Street Analyst
Ranked #3,348 out of 8,047 Analysts on TipRanks (#6,981 out of 21,521 overall experts)

Success Rate

39%
130 out of 331 Profitable Transactions

Average Return

1.70%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Derek Archila's ratings since 2017 and opened each position for the duration of 1 Year:
39.27% of your transactions would have been profitable with an average return of 1.7%

Stock Rating Distribution

667Ratings
64.47% Buy
34.78% Hold
0.75% Sell
Distribution of Derek Archila's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market
United KingdomUK Market

Best Rating

Stock:
Principia Biopharma
(PRNB)
Rating Type:Buy
Dates:Oct 02, 2019 - Aug 19, 2020
Gain:267.30%
The most profitable rating made by Derek Archila

Derek Archila's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Zogenix
Hold
Assigned
100%
+11.90%
2
Viatris
Hold
Reiterated
0.00%
1
Tempest Therapeutics
Hold
Reiterated
0.00%
8
Teva Pharmaceutical
Hold
Assigned
0%
-27.54%
18
Endo International
Hold
Reiterated
0.00%
12
Mallinckrodt
Hold
Reiterated
0%
-51.41%
9
Perrigo Company
Buy
Reiterated
$98.00
(134.06% Upside)
0%
-30.90%
6
Insys Therapeutics
Hold
Reiterated
0.00%
8
Zynerba Pharmaceuticals
Hold
Reiterated
0%
-51.90%
11
Synergy Pharmaceuticals Inc
Hold
Reiterated
0%
-34.30%
15
List of latest recommendations made by Derek Archila. Click to expand and see Derek Archila's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More